What is Faks?
Founded in 2020 and headquartered in Paris, Faks offers a secure, modular, and neutral communication platform designed to streamline operations and foster collaboration within the pharmaceutical ecosystem. The application serves over 17,000 pharmacies, 500 laboratories, and 130 pharmacy groups, addressing critical needs such as expired medication management, claims processing, and trade campaigns. Faks's innovative solution aims to enhance efficiency and business relationships for pharmacy professionals, positioning it as a key player in the digital transformation of the sector.
How much funding has Faks raised?
Faks has raised a total of $11.6M across 2 funding rounds:
Other Financing Round
$5.4M
Other Financing Round
$6.2M
Other Financing Round (2023): $5.4M with participation from Cocoa Ventures, Connect Ventures, and Seedcamp
Other Financing Round (2025): $6.2M led by Seedcamp, FJ Labs, Speedinvest, and Connect Ventures
Key Investors in Faks
Seedcamp
Seedcamp is a venture capital firm that supports early-stage startups by providing investment, mentorship, and access to a global network. The firm focuses on ambitious founders and innovative companies across various sectors, helping them grow from initial concepts to successful businesses.
FJ Labs
FJ Labs specializes in angel investing at a venture scale, focusing on marketplaces and network effect businesses. They have invested in notable companies such as Alibaba, Coupang, and Rappi, building the world's largest portfolio of marketplace startups, with over 30 achieving unicorn status.
Speedinvest
Speedinvest is a venture capital fund with over €1B allocated for investing in pre-Seed, Seed, and early-stage tech startups across Europe. The company focuses on various sectors including Deep Tech, Fintech, Health Bio, Climate Tech, and SaaS Infra.
What's next for Faks?
With the recent infusion of $6.2M in strategic capital, Faks is poised for accelerated expansion and further development of its platform. This enterprise-level funding suggests a focus on scaling operations, enhancing technological capabilities, and potentially broadening its market reach. The company's trajectory indicates a move towards solidifying its position as an indispensable tool for pharmaceutical stakeholders, likely involving deeper integration with existing healthcare IT infrastructure and the introduction of new collaborative features.
See full Faks company page
